Oncology Medications

Imbruvica – New Formulation

 

IMBRUVICA® (ibrutinib) – New Formulation
Available For Prescription Order Today!

Onco360 has been selected to the extremely limited distribution network of
Specialty Pharmacies for IMBRUVICA (ibrutinib).

 

IMBRUVICA Indications

IMBRUVICA (ibrutinib) has been approved by the FDA for the four following indications and is available for prescription order through Onco360

APPROVED INDICATIONS1 RECOMMENDED DOSAGE2
Chronic lymphocytic leukemia (CLL) patients 420 mg orally once daily
CLL patients with 17p deletion 420 mg orally once daily
Waldenström’s macroglobulinemia (WM) patients 420 mg orally once daily
Mantle cell lymphoma (MCL) patients who have received
at least one prior treatment
560 mg orally once daily
Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy 560 mg taken orally once daily  

 

Eligible patients who are prescribed IMBRUVICA may receive access support through the YOU&i Access Program. More information is available at: 877-877-3536 or at www.imbruvica.com/youandi.

For more information about IMBRUVICA, please visit IMBRUVICA.com.

Reference:

  1. www.imbruvica.com
  2. Imbruvica Prescribing Information

All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.